China SXT Pharmaceuticals, Inc.SXTC
Price (close)
$2.55
Market cap
—
P/E
—
Revenue (FY)
$1.1M
Net income
-$6.2M
Dividend yield
—
1-year total return
-100.0%
Net margin
-545.2%
Revenue growth
-34.6%
Debt / equity
0.03x
What China SXT Pharmaceuticals, Inc. does.
company conducting all of our business through our subsidiaries and variable interest entity, Taizhou Suxuantang in China. Neither we
nor our subsidiaries own any share in Taizhou Suxuantang. Instead, WFOE, Taizhou Suxuantang and its shareholders entered into a series
of contractual arrangements, also known as VIE Agreements, pursuant to which, we are regarded as the primary beneficiary of Taizhou Suxuantang
Revenue and profit, by fiscal year.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Revenue | $4.8M | $2.6M | $2.0M | $1.9M | $1.7M | $1.1M |
| Net income | -$2.7M | -$5.7M | -$5.9M | -$3.1M | -$3.3M | -$6.2M |
| Free cash flow | -$1.4M | $207,361 | — | -$1.9M | -$2.3M | — |
More on SXTC.
- China SXT Pharmaceuticals, Inc. summary
- China SXT Pharmaceuticals, Inc. financial statements
- China SXT Pharmaceuticals, Inc. key metrics
- China SXT Pharmaceuticals, Inc. health scores and style box
- China SXT Pharmaceuticals, Inc. earnings
- China SXT Pharmaceuticals, Inc. dividends
- China SXT Pharmaceuticals, Inc. valuation
- China SXT Pharmaceuticals, Inc. ownership and insiders
- China SXT Pharmaceuticals, Inc. peers
Figures from China SXT Pharmaceuticals, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.